CINECA IRIS Institutional Research Information System

CIAMPI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.353
EU - Europa 3.511
AS - Asia 726
AF - Africa 156
SA - Sud America 24
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.779
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.233
IT - Italia 1.379
DE - Germania 756
SE - Svezia 596
CN - Cina 358
BG - Bulgaria 206
GB - Regno Unito 184
AT - Austria 152
CA - Canada 120
CI - Costa d'Avorio 105
SG - Singapore 91
IN - India 80
TR - Turchia 75
VN - Vietnam 69
FI - Finlandia 54
RU - Federazione Russa 54
UA - Ucraina 51
SN - Senegal 45
HK - Hong Kong 25
CH - Svizzera 20
BR - Brasile 19
FR - Francia 17
BE - Belgio 13
PL - Polonia 8
IR - Iran 7
AU - Australia 4
IL - Israele 4
TW - Taiwan 4
CL - Cile 3
EU - Europa 3
GR - Grecia 3
HU - Ungheria 3
JP - Giappone 3
NG - Nigeria 3
BY - Bielorussia 2
DK - Danimarca 2
ES - Italia 2
ID - Indonesia 2
KR - Corea 2
NZ - Nuova Zelanda 2
RO - Romania 2
RS - Serbia 2
AZ - Azerbaigian 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
IS - Islanda 1
JO - Giordania 1
NL - Olanda 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 8.779
Salva come PNG Salva come JPEG
Città #
Woodbridge 593
Fairfield 465
Chandler 395
Ann Arbor 393
Houston 341
Ashburn 296
Milan 247
Sofia 206
Seattle 171
Wilmington 168
Beijing 153
Cambridge 152
Vienna 146
New York 141
Ottawa 109
Abidjan 105
Princeton 91
Lawrence 76
Pisa 73
Medford 65
Rome 64
Serra 63
Izmir 61
Jacksonville 58
Florence 55
Dearborn 54
Nanjing 51
Dakar 45
Des Moines 45
London 41
Bremen 37
Frankfurt am Main 33
San Diego 32
Dong Ket 24
Naples 23
Redmond 23
Hong Kong 21
Redwood City 21
Boulder 20
Lancaster 20
Nanchang 20
Bologna 19
Bern 15
Shanghai 14
Bengaluru 13
Brussels 12
Düsseldorf 12
Hangzhou 11
Jaboatão 11
Jüchen 11
Washington 11
Changsha 10
Jiaxing 10
Trieste 10
Verona 10
Bhavnagar 9
Kunming 9
Los Angeles 9
Norwalk 9
Shenyang 9
Tianjin 9
Turin 9
Guangzhou 8
Kocaeli 8
Livorno 8
San Giuliano Terme 8
Wuhan 8
Cuneo 7
Dallas 7
Hefei 7
Indiana 7
Jinan 7
Montale 7
Mumbai 7
Parma 7
Cascina 6
Chengdu 6
Chiesina Uzzanese 6
Hebei 6
La Spezia 6
Messina 6
Ogden 6
Trevignano 6
Acerra 5
Angri 5
Bari 5
Brescia 5
Buffalo 5
Cervignano del Friuli 5
Genoa 5
Grafing 5
Gurgaon 5
Modena 5
Napoli 5
Pune 5
San Francisco 5
Singapore 5
Toronto 5
Urmia 5
Auburn Hills 4
Totale 5.657
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 684
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 217
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 191
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 189
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 169
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 165
null 160
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 160
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 158
null 157
Targeted Therapy in Thyroid Cancer: State of the Art 149
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 146
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 146
null 145
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 143
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 141
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 141
BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer 135
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 131
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 126
null 122
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 121
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 121
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization 118
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 118
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 117
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 115
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 115
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 114
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 113
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 111
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 109
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 108
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 103
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors 102
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 102
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 102
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 100
null 99
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 98
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 97
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 96
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 91
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 90
Alterations of the BRAF gene in thyroid tumors 87
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RAR{beta} mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 86
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid 83
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 82
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation 82
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas 82
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 79
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 79
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 79
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 77
Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis 77
HOOK3-RET: A novel type of RET/PTC rearrangement in papillary thyroid carcinoma 76
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 76
null 75
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes 74
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer 74
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 74
Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis 72
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 71
null 70
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 67
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity 66
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 63
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 61
null 58
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 58
Studi in vitro del trattamento con acido retinoico di linee cellulari di carcinoma tiroideo umano anaplastico, scarsamente differenziato, follicolare e midollare 57
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation 56
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 56
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 54
null 51
SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN 50
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 50
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 44
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 43
RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 42
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 40
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 36
Genetic heterogeneity of Medullary Thyroid Carcinoma 28
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 25
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 24
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 24
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 22
Ret Oncogene and Thyroid Carcinoma 20
Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes 19
The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma 17
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 16
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 11
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 8
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients 3
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value 2
Totale 8.961
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019514 0 0 0 0 0 0 0 0 0 160 195 159
2019/20201.651 182 105 112 94 159 198 165 108 130 146 206 46
2020/2021702 76 81 66 22 34 37 79 61 59 59 37 91
2021/20221.073 38 58 21 75 213 133 35 47 56 49 78 270
2022/20231.746 209 252 138 135 141 188 62 125 313 37 108 38
2023/20241.191 156 131 126 110 168 203 118 80 62 37 0 0
Totale 8.961